Introduction {#section5-1758835920907534}
============

Patients with differentiated thyroid cancer (DTC) may present with unfavorable prognostic factors. The five-year cancer-specific survival for patients presenting with distant metastases is only 40%^[@bibr1-1758835920907534],[@bibr2-1758835920907534]^ as these patients frequently become refractory to radioiodine^[@bibr3-1758835920907534],[@bibr4-1758835920907534]^ despite the advent of tyrosine kinase inhibitors (TKI).^[@bibr5-1758835920907534]^

To date, DTC risk stratification based on clinicopathological tumor characteristics remains an imperfect science. Recent research has focused on the identification of genetic markers, including *BRAF* and *RAS* mutations, as well as *RET/PTC* and *PAX8/PPAR gamma* rearrangements to improve risk stratification.^[@bibr2-1758835920907534],[@bibr5-1758835920907534]^

New data are emerging for DTC from the use of genome-analyzing methods such as high-throughput next-generation sequencing (NGS),^[@bibr6-1758835920907534]^ yielding a so-called molecular signature^[@bibr7-1758835920907534]^ that may in the future become a clinically valuable tool for diagnosis, risk stratification, and personalized therapy.^[@bibr5-1758835920907534],[@bibr8-1758835920907534]^ Furthermore, the definition of the spectrum and patterns of driver gene mutations in DTC may lead to the identification of targets for new treatments.

Although the Cancer Genome Atlas consortium has delivered new data on the genetic background of the papillary subvariety of DTC,^[@bibr7-1758835920907534]^ follicular thyroid cancer (FTC) has not yet been addressed.^[@bibr9-1758835920907534]^ The aim of the present study was to establish a mutational profile of FTC and to identify potential new mutations associated with FTC employing high-throughput NGS technology.

Material and methods {#section6-1758835920907534}
====================

Ethical approval {#section7-1758835920907534}
----------------

The study was approved by the Bioethical Committee of the Poznań University of Medical Sciences (an approval no. 1061/15 from January 2015) and was conducted in accordance with the Declaration of Helsinki. Before surgery, patients gave generalized written informed consent for the use of their materials for scientific purposes and therefore the need for a specific written informed consent pertaining to the present study only was waived by the bioethical committee.

Study background {#section8-1758835920907534}
----------------

NGS sequencing was conducted using an Ion Personal Genome Machine Sequencer (Thermo Fisher Scientific; Indianapolis, USA) employing the Ion AmpliSeq Comprehensive Cancer Panel. The data obtained from genomic experiments were subjected to analysis using the dedicated software Variant Caller v5.2.1.38 (Thermo Fisher Scientific; Indianapolis, USA) and MutationTaster2 (Berlin Institute of Health, Berlin, Germany).

Patient characteristics {#section9-1758835920907534}
-----------------------

### Index patient {#section10-1758835920907534}

The study was initiated based on clinical data obtained from an index patient, in whom the presence of mutations of the hot spot class III receptor fms-like tyrosine kinase-3 (*FLT3*; fetal liver kinase-2; human stem cell tyrosine kinase-1; CD135) was identified. This concerned a 29-year-old female patient diagnosed with FTC and metastases to the lymph nodes and lungs, who required two subsequent lymphadenectomies followed by three courses of radioiodine therapy (2009--2011). Due to unsatisfactory results, the patient was subsequently treated with lenvatinib from 2012--2015 and achieved total structural and partial biochemical remission. However, after 3 years, locoregional disease recurrence was found, and the drug was withdrawn. The patient was then re-operated on and received the last radioiodine therapy in 2015 and has been treated with sorafenib since 2016. Complete remission was not yet achieved at the last follow-up in June 2018.

In this index patient, DNA was isolated from a formalin-fixed, paraffin-embedded (FFPE) FTC specimen acquired at thyroidectomy in 2006. The specimen was re-reviewed to confirm the diagnosis and to indicate the most appropriate part for DNA sample collection.

### Data collection {#section11-1758835920907534}

We analyzed 35 randomly selected patients \[computer-aided simple random sampling (generated at [stattrek.com](http://stattrek.com))\] at the tertiary care department of endocrinology at our university hospital, who were diagnosed with FTC according to the revised World Health Organization criteria from 2004,^[@bibr10-1758835920907534]^ between the years 2006 and 2018. Surgically obtained FTC specimens were subjected to further molecular analyses. The group consisted of 31 women and four men, all White, with a median age at diagnosis of 52 years (range 27--82 years). Only patients not already receiving treatment, which might affect the molecular signature of thyroid cancer at the time of diagnosis, nor suffering from any other endocrine disorders or cancer, were enrolled in the study. The single exclusion criterion was a patient's medical records being incomplete.

Follow-up data on patients were collected up to July 2018.

Molecular studies and clinical analysis {#section12-1758835920907534}
---------------------------------------

Assessment of *FLT3* mutational positivity was conducted with NGS sequencing. All specimens were reassessed by two independent board-certified pathologists to confirm the diagnosis and to indicate the most appropriate part for DNA sample collection, meaning those which most fulfilled FTC criteria such as vascular or capsular invasion. DNA was extracted with the High Pure FFPET DNA Isolation Kit (Roche Life Science, Indianapolis, USA) from FFPE FTC specimens obtained during thyroidectomy.^[@bibr11-1758835920907534]^ The Next Generation Sequencing Library was constructed with the Ion AmpliSeq^™^ Library Kit 2.0. (Life Technologies, Darmstadt, Germany). The template was prepared on the Ion OneTouch system (Thermo Fisher Scientific; Indianapolis, USA). Finally, DNA high-throughput sequencing was performed on the Ion PGM Sequencer (Thermo Fisher Scientific, Indianapolis, USA) with the Ion PGM^™^ Hi-Q^™^ Sequencing Kit (Life Technologies, Darmstadt, Germany) on the Ion 318^™^ sequencing chip (Life Technologies, Darmstadt, Germany).

An NGS Ion AmpliSeq Cancer Hotspot Panel v2 (Thermo Fisher Scientific, Indianapolis, USA) was used to study the coding regions and intronic flanking regions of the *FLT3* gene. The analysis of other genes included in NGS Ion AmpliSeq Cancer Hotspot Panel v2, concerning the amount of data and the clarity of the presentation of results, is the subject of a separate report (submitted). Based on the costs, capacity, and analytical experience, in accordance with the guidelines for a comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing,^[@bibr12-1758835920907534]^ we determined a minimum of 30 × depth of sequencing coverage of each the tumor and normal genomes with paired reads on the order of 100--250 bp in length to identify tumor-specific somatic mutations.^[@bibr12-1758835920907534],[@bibr13-1758835920907534]^

Data obtained were subjected to further analysis using the Variant caller v5.2.1.38 software (Thermo Fisher Scientific; Indianapolis, USA) and the MutationTaster2 algorithm.^[@bibr14-1758835920907534]^ Furthermore, to analyze a putative function of *FLT3* mutations as driver mutations, four separate programs were employed: SIFT,^[@bibr15-1758835920907534]^ PolyPhen-2 (Polymorphism Phenotyping v2),^[@bibr16-1758835920907534]^ and MutationTaster2,^[@bibr14-1758835920907534]^ as well as FATHMM (Functional Analysis through Hidden Markov Models v2.3), which result in an index, calculated with a high-throughput web-server, which is able to predict the functional consequences of both coding variants, that is, nonsynonymous single nucleotide variants, and noncoding variants to distinguish between cancer-promoting/driver mutations and other germline polymorphisms.

The Catalogue of Somatic Mutations in Cancer (COSMIC), the dbSNP, 1000 Genome Project, ClinVar, and ExAC databases were checked for existing reports of the presence of particular *FLT3* mutations. For the validation of mutations, we selected tissues bearing the most common mutations and performed a Sanger sequencing (Thermo Fisher Scientific; Indianapolis, USA).^[@bibr17-1758835920907534]^ Selected tissues were showing at least 20% tumor cell content to ensure a minimal threshold level for sensitivity using the di-deoxy method. The amplifications of selected targets were conducted using Clontech Titanium^™^ DNA Amplification Kit (Takara Bio Inc., Japan) and processed through 35 cycles (30s at 94°C, 30 s at 60°C, and 45s at 72°C). Primers were designed using the Primer3 Design Tool.^[@bibr18-1758835920907534],[@bibr19-1758835920907534]^ The primers were as follows: exon 4 forward 5′- tctgaggggctgctaagag -3′, exon 4 reverse 5′- cgaaatgctgggattacagg -3′, exon 10 forward 5′- ccaccttggcttcacaaag -3′, exon 10 reverse 5′- aggatttctgcagcgagttc -3′, exon 13 forward 5′- tttccaaaagcacctgatcc -3′, exon 13 reverse 5′- ccttccctttcatccaagac -3′, exon 19 forward 5′- ccatcaccggtacctcctac -3′, exon 19 reverse 5′- ccctgaagctgcagaaaaac-3′. Capillary sequencing was conducted with the use of BigDye chemistry version 3.1, on an ABI 3130xl DNA Analyzer according to manufacturer instructions (Applied Biosystems, Foster City, CA). Sequence traces from tumor DNA samples were aligned to the genomic reference sequence of *FLT3* gene (NG_007066_1) and analyzed using CodonCode Aligner software version 4.0.4 (<http://www.codoncode.com>).

Clinical data {#section13-1758835920907534}
-------------

Clinical records and results of histopathological examinations of the resected specimen following thyroidectomy were analyzed for all patients.

The following data were recorded from patient files: gender, age at diagnosis, tumor size, multifocality, capsular invasion without extra-thyroidal extension, presence of histopathological signs of chronic lymphocytic thyroiditis (presence of diffuse lymphocytic infiltrate, oxyphilic cells, and the formation of primary and secondary lymphoid follicles^[@bibr20-1758835920907534]^), and histopathological staging.

Tumors were classified as multifocal when two or more foci were found. In the case of multifocality, the size of a tumor was staged by the size of the largest focus. Staging procedures were performed according to the joint Union Contre le Cancer and American Joint Committee on Cancer Tumor, Node Metastasis (TNM) staging system (7th Edition).^[@bibr21-1758835920907534]^

For the present study, patients were defined as radioactive iodine (RAI) refractory if a cumulative activity of 22.2 GBq/600 mCi of RAI therapy were given without achieving complete remission.

Statistical analysis {#section14-1758835920907534}
--------------------

The parameters were recorded and entered into a dedicated database. Descriptive analysis was used to summarize the collected data. To determine the normality of continuous variables, data were tested by the D'Agostino and Pearson omnibus normality test. Variables that were found to be normally distributed were expressed as means with respective standard deviations. Non-normal data were expressed as median and minimum-maximum values.

To compare differences between groups, the chi-square test or Fisher's exact test (2 × 2 contingency table) were used as appropriate for categorical variables. Interval data were compared with the use of the Mann--Whitney *U* test as the data did not follow a normal distribution. Odds ratio (OR) and the 95% confidence interval (95% CI) were calculated using the group of *FLT3* mutation-negative patients as the reference population. Correlation between the number of mutations in a single patient and their age was assessed with Pearson's *r* correlation test.

A *p*-value \<0.05 was regarded as significant. Statistical analyses were performed with StatSoft Statistica v10.0 and Analyse-It for Microsoft Excel v3.53.

Data availability {#section15-1758835920907534}
-----------------

The datasets were submitted to the publicly accessible Catalogue of Somatic Mutations in Cancer (COSMIC) database.

Results {#section16-1758835920907534}
=======

Index patient {#section17-1758835920907534}
-------------

The analysis revealed the presence of an *FLT3* (fetal liver kinase-2; human stem cell) mutation on chromosome 13 -- a heterozygous mutation c.1683A\>G (p.L561L, COSM19740) in the *FLT3* gene.

The mutation was not detected in the patient's leucocyte DNA through NGS, confirming its somatic character. This particular mutation has not been detected in any other FTC specimen. Extension of the analysis using bioinformatic tools including SIFT, Polyphen-2, and MutationTaster2,^[@bibr14-1758835920907534]^ found further *FLT3* mutations as described in [Table 1](#table1-1758835920907534){ref-type="table"}. Fifteen further mutations were identified as potentially disease-causing, (i.e. driver), mutations. All have been previously published in the COSMIC database in acute myeloid leukemia (AML), although have not been previously reported in FTC. A total of 60% have been identified in acute lymphocytic leukemia (ALL) and a minority in myelodysplastic syndrome (MDS), lung adenocarcinoma, and gastric cancer. Two mutations may be sufficient to cause resistance to sorafenib (*FLT3* D835H and D835Y),^[@bibr22-1758835920907534]^ quizartinib (D835V and D835Y),^[@bibr23-1758835920907534]^ and even one-to sunitinib (D835Y).^[@bibr24-1758835920907534],[@bibr25-1758835920907534]^

###### 

The list of *FLT3* mutations (Ensembl transcript ID: ENST0000241453 and Genbank transcript ID: NM_004119, UniProt number P36888) predicted as "disease-causing" by MutationTaster algorithm in CDS (alteration region).

![](10.1177_1758835920907534-table1)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  AAE     Type                                            Alteration (physical location)   DNA changes                               dbSNP or rs   COSMIC mutation ID   Previously reported    ClinVar probability of disease causing/FATHMM prediction   Drug resistance
  ------- ----------------------------------------------- -------------------------------- ----------------------------------------- ------------- -------------------- ---------------------- ---------------------------------------------------------- -----------------
  V194M   Single base exchange -Substitution - Missense   chr13:28626716C\>T               c.580G\>A\                                rs146030737   COSM28039            AML\                   0.51/0.45                                                  --
                                                                                           cDNA.662G\>A\                                                                Lung adenocarcinoma\                                                              
                                                                                           g.48014G\>A                                                                  Gastric cancer                                                                    

  S451F   Single base exchange -Substitution - Missense   chr13:28610138G\>A               c.1352C\>T\                               --            COSM28042            AML                    0.99/0.98                                                  --
                                                                                           cDNA.1434C\>T\                                                                                                                                                 
                                                                                           g.64592C\>T                                                                                                                                                    

  Y572C   Single base exchange -Substitution - Missense   chr13:28608341T\>C               c.1715A\>G\                               rs121913491   COSM28044            AML\                   0.99/0.99                                                  --
                                                                                           cDNA.1797A\>G\                                                               ALL\                                                                              
                                                                                           g.66389A\>G                                                                  MDS                                                                               

  V592A   Single base exchange -Substitution - Missense   chr13:28608281A\>G               c.1775T\>C\                               --            COSM19522            AML                    0.99/0.99                                                  --
                                                                                           cDNA.1857T\>C\                                                                                                                                                 
                                                                                           g.66449T\>C                                                                                                                                                    

  Y599F   Single base exchange -Substitution - Missense   chr13:28608260T\>A               c.1796A\>T\                               --            COSM27906            AML                    0.99/0.99                                                  --
                                                                                           cDNA.1878A\>T\                                                                                                                                                 
                                                                                           g.66470A\>T                                                                                                                                                    

  G831E   Single base exchange -Substitution - Missense   chr13:28592653C\>T               c.2492G\>A\                               --            COSM25248            AML\                   0.99/0.99                                                  --
                                                                                           cDNA.2574G\>A\                                                               T ALL                                                                             
                                                                                           g.82077G\>A                                                                                                                                                    

  R834Q   Single base exchange -Substitution - Missense   chr13:28592644C\>T               c.2501G\>A\                               --            COSM28047            AML\                   0.99/0.99                                                  --
                                                                                           cDNA.2583G\>A\                                                               B ALL                                                                             
                                                                                           g.82086G\>A                                                                                                                                                    

  D835A   Single base exchange                            chr13:28592641T\>G               c.2504A\>C\                               --            COSM27650            AML\                   0.99/0.99                                                  --
                                                                                           cDNA.2586A\>C\                                                               ALL                                                                               
                                                                                           g.82089A\>C                                                                                                                                                    

  D835E   Single base exchange -Substitution - Missense   chr13:28592640A\>T               c.2505T\>A\                               rs121913487   COSM787              AML                    0.99/0.88                                                  --
                                                                                           cDNA.2587T\>A\                                                                                                                                                 
                                                                                           g.82090T\>A                                                                                                                                                    

  D835E   Single base exchange -Substitution - Missense   chr13:28592640A\>C               c.2505T\>G\                               --            COSM788              AML                    0.99/0.89                                                  --
                                                                                           cDNA.2587T\>G\                                                                                                                                                 
                                                                                           g.82090T\>G                                                                                                                                                    

  D835H   Single base exchange -Substitution - Missense   chr13:28592642C\>G               c.2503G\>C\                               rs121913488   COSM785              AML\                   0.99/0.99                                                  Sorafenib
                                                                                           cDNA.2585G\>C\                                                               B ALL                                                                             
                                                                                           g.82088G\>C                                                                                                                                                    

  D835N   Single base exchange -Substitution - Missense   chr13:28592642C\>T               c.2503G\>A\                               rs121913488   COSM789              AML\                   0.99/0.99                                                  --
                                                                                           cDNA.2585G\>A\                                                               ALL                                                                               
                                                                                           g.82088G\>A                                                                                                                                                    

  D835V   Single base exchange -Substitution - Missense   chr13:28592641T\>A               c.2504A\>T\                               rs121909646   COSM784              AML\                   0.99/0.99                                                  Quizartinib
                                                                                           cDNA.2586A\>T\                                                               ALL                                                                               
                                                                                           g.82089A\>T                                                                                                                                                    

  D835Y   Single base exchange -Substitution - Missense   chr13:28592642C\>A               c.2503G\>T\                               rs121913488   COSM783              AML\                   0.99/0.99                                                  Quizartinib\
                                                                                           cDNA.2585G\>T\                                                               ALL                                                                               Sorafenib\
                                                                                           g.82088G\>T                                                                                                                                                    Sunitinib

  I836-   Deletion -- In frame                            chr13:28592635_28592637delATG    c.2508_2510delCAT cDNA.2590_2592delCAT\   rs121913490   COSM19836            AML\                   0.99/--                                                    --
                                                                                           g.82093_82095delCAT                                                          ALL\                                                                              
                                                                                                                                                                        B ALL                                                                             
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AAE, amino acid exchange; DNA, Deoxyribonucleic acid; dbSNP, The Single Nucleotide Polymorphism Database; rs, reference SNP identifying number; COSMIC, The Catalogue of Somatic Mutations in Cancer; ID, identifier; FATHMM, Functional Analysis through Hidden Markov Models v2.3; AML, acute myeloid leukemia; ALL, acute lymphocytic leukemia; MDS, myelodysplastic syndrome; B ALL, B-cell acute lymphocytic leukemia

Study patients {#section18-1758835920907534}
--------------

*FLT3* mutational status in the larger group of patients diagnosed with FTC enabled discrimination between *FLT3* wild type patients (*n* = 11; 31%), without detectable mutation in the *FLT3* gene, considered as '*FLT3* negative', and patients with at least one mutation in the *FLT3* gene, considered '*FLT3* positive' (*n* = 24; 69%).

The demographic and clinical features of both groups are presented in [Table 2](#table2-1758835920907534){ref-type="table"}. *FLT3*-positive patients were found to be significantly older than *FLT3-*negative patients with a median age at diagnosis of 54 (36--82) *versus* 45 (27--58) years (*p* = 0.023). Patients over 60 years were 23 times more likely to be *FLT3* positive \[*p* = 0.006, OR = 23.0 (95% CI: 1.22--434.20)\]. There was no significant difference with regard to the distribution of sex, multifocality, capsule invasion, extracapsular extension, nodal involvement, mean tumor size, localization, or the presence of chronic lymphocytic thyroiditis.

###### 

Patients characteristics due to *FLT3* mutational status.

![](10.1177_1758835920907534-table2)

  Characteristics                                                *FLT3* negative^[\*](#table-fn3-1758835920907534){ref-type="table-fn"}^    *FLT3* positive^[\*](#table-fn3-1758835920907534){ref-type="table-fn"}^
  -------------------------------------------------------------- -------------------------------------------------------------------------- --------------------------------------------------------------------------
  Number of patients (%)                                         11 (31)                                                                    24 (69)
  Male/female, *n* (%)                                           1/10 (9/91)                                                                2/22 (8/92)
  **Median age at diagnosis, years (range)**                     **45 (27--58)** ^[\*](#table-fn3-1758835920907534){ref-type="table-fn"}^   **54 (36--82)** ^[\*](#table-fn3-1758835920907534){ref-type="table-fn"}^
  **Age group**                                                                                                                             
   **⩽60 years (%)**                                             **11 (100)** ^[\*](#table-fn3-1758835920907534){ref-type="table-fn"}^      **12 (50)** ^[\*](#table-fn3-1758835920907534){ref-type="table-fn"}^
   **\>60 years (%)**                                            **0** ^[\*](#table-fn3-1758835920907534){ref-type="table-fn"}^             **12 (50)** ^[\*](#table-fn3-1758835920907534){ref-type="table-fn"}^
  Length of follow-up, months (range)                            27 (11--127)                                                               92 (10--142)
  Multifocality, *n* (%)                                         0                                                                          2 (8)
  Capsule invasion, *n* (%)                                      5 (45)                                                                     10 (50)
  Extracapsular extension, *n* (%)                               10 (91)                                                                    18 (75)
  Nodal (N) involvement, *n* (%)                                 0                                                                          2 (8)
  Mean tumor size, mm (range)                                    32 (7--80)                                                                 28 (12--75)
  Tumor diameter ⩽10 mm, *n* (%)                                 1 (9)                                                                      0
  Localization in the right lobe/left lobe/both lobes, *n* (%)   6/5/0 (55/45/0)                                                            14/9/1 (58/38/4)
  Chronic lymphocytic thyroiditis                                2 (18)                                                                     7 (29)
  Radioactive iodine-refractoriness                              0                                                                          2 (8)

CI, confidence interval; OR, odds ratio.

The differences between groups, except for the bold elements denoted by asterisk (^\*^): median age at diagnosis (*p* = 0.023), age group distribution \[*p* = 0.006, OR = 23.0 (95% CI: 1.22--434.20)\], were nonsignificant at *p* \< 0.05 with Fisher's exact test and Mann--Whitney *U* test, as appropriate.

A total of 26 *FLT3* gene mutations were identified with coverage of \>30× ([Table 3](#table3-1758835920907534){ref-type="table"}). The mean sequencing coverage of the target region across all samples was 60-fold. The most common mutations were single base exchanges in the form of missense substitutions. The most frequent mutations were V592A and Y599F in 10 patients, and G831E, R834Q, D835H, D835N, D835Y in nine patients (the last three mutations localized in the tyrosine kinase domain). In total, 2--16 *FLT3* mutations were found in every *FLT3*-positive patient, with a mean of 5.6 mutations per patient, and protein kinase domain mutations were identified in the *FLT3* gene in 14 patients (58%).

###### 

The list of *FLT*3 mutations with Ensembl transcript ID: ENST0000241453 and Genbank transcript ID: NM_004119 in peptide with UniProt number P36888 predicted as "disease-causing" by MutationTaster algorithm in CDS (alteration region).

![](10.1177_1758835920907534-table3)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  AAE             Type                                              Alteration (physical location)     DNA changes                               dbSNP or rs   COSMIC mutation ID   Previously reported                                ClinVar probability of disease causing/FATHMM prediction   Total number of patients with the mutation (%)
  --------------- ------------------------------------------------- ---------------------------------- ----------------------------------------- ------------- -------------------- -------------------------------------------------- ---------------------------------------------------------- ------------------------------------------------
  S451F           Single base exchange -Substitution - Missense     chr13:28610138G\>A                 c.1352C\>T\                               --            COSM28042            AML                                                0.99/0.98                                                  8
                                                                                                       cDNA.1434C\>T\                                                                                                                                                                             
                                                                                                       g.64592C\>T                                                                                                                                                                                

  Y572C           Single base exchange -Substitution - Missense     chr13:28608341T\>C                 c.1715A\>G\                               rs121913491   COSM28044            AML\                                               0.99/0.99                                                  6
                                                                                                       cDNA.1797A\>G\                                                               ALL\                                                                                                          
                                                                                                       g.66389A\>G                                                                  MDS                                                                                                           

  V592A           Single base exchange -Substitution - Missense     chr13:28608281A\>G                 c.1775T\>C\                               --            COSM19522            AML                                                0.99/0.99                                                  10
                                                                                                       cDNA.1857T\>C\                                                                                                                                                                             
                                                                                                       g.66449T\>C                                                                                                                                                                                

  E598K           Single base exchange -Substitution - Missense     chr13:28608264C\>T                 c.1792G\>A\                               --            COSM6005766          Malignant melanoma, Vulvar squamus cel carcinoma   0.64/0.88                                                  1
                                                                                                       cDNA.1874G\>A\                                                                                                                                                                             
                                                                                                       g.66466G\>A                                                                                                                                                                                

  Y599F           Single base exchange -Substitution - Missense     chr13:28608260T\>A                 c.1796A\>T\                               --            COSM27906            AML                                                0.99/0.99                                                  10
                                                                                                       cDNA.1878A\>T\                                                                                                                                                                             
                                                                                                       g.66470A\>T                                                                                                                                                                                

  D600G           Single base exchange -Substitution - Missense     chr13:28608257T\>C                 c.1799A\>G\                               --            --                   --                                                 0.99/--                                                    1
                                                                                                       cDNA.1881A\>G\                                                                                                                                                                             
                                                                                                       g.66473A\>G                                                                                                                                                                                

  K602R           Single base exchange -Substitution - Missense     chr13:28608251T\>C                 c.1805A\>G\                               --            --                   --                                                 0.99/--                                                    1
                                                                                                       cDNA.1887A\>G\                                                                                                                                                                             
                                                                                                       g.66479A\>G                                                                                                                                                                                

  W603^\*^        Single base exchange - Substitution - Nonsense    chr13:28608248C\>T                 c.1808G\>A\                               --            COSM6342211          Colorectal adenocarcinoma                          1.00/0.99                                                  1
                                                                                                       cDNA.1890G\>A\                                                                                                                                                                             
                                                                                                       g.66482G\>A                                                                                                                                                                                

  E604K           Single base exchange                              chr13:28608246C\>T                 c.1810G\>A\                               --            --                   --                                                 0.99/--                                                    1
                                                                                                       cDNA.1892G\>A\                                                                                                                                                                             
                                                                                                       g.66484G\>A                                                                                                                                                                                

  E672Gfs^\*^21   Insertion                                         chr13:28602353_28602354insC        c.2014_2015insG\                          --            --                   --                                                 1.00/--                                                    1
                                                                                                       cDNA.2074_2075insG\                                                                                                                                                                        
                                                                                                       g.72376_72377insG                                                                                                                                                                          

  A680V           Single base exchange - Substitution - Missense    chr13:28602329G\>A                 c.2039C\>T\                               rs372303125   COSM786              AML\                                               0.99/0.99                                                  7
                                                                                                       cDNA.2121C\>T\                                                               B ALL\                                                                                                        
                                                                                                       g.72401C\>T                                                                  Blastic plasmacytoid dendritic cell neoplasm\                                                                 
                                                                                                                                                                                    Lung large cell carcinoma\                                                                                    
                                                                                                                                                                                    Intestinal adenocarcinoma\                                                                                    
                                                                                                                                                                                    Thyroid papillary carcinoma                                                                                   

  G831E           Single base exchange - Substitution - Missense    chr13:28592653C\>T                 c.2492G\>A\                               --            COSM25248            AML\                                               0.99/0.99                                                  9
                                                                                                       cDNA.2574G\>A\                                                               T ALL                                                                                                         
                                                                                                       g.82077G\>A                                                                                                                                                                                

  G831R           Single base exchange - Substitution - Missense    chr13:28592654C\>T                 c.2491G\>A\                               --            COSM6342208          Colon adenocarcinoma                               0.99/0.99                                                  1
                                                                                                       cDNA.2573G\>A\                                                                                                                                                                             
                                                                                                       g.82076G\>A                                                                                                                                                                                

  R834Q           Single base exchange - Substitution - Missense    chr13:28592644C\>T                 c.2501G\>A\                               --            COSM28047            AML\                                               0.99/0.99                                                  9
                                                                                                       cDNA.2583G\>A\                                                               B ALL                                                                                                         
                                                                                                       g.82086G\>A                                                                                                                                                                                

  D835-           Deletion\                                         chr13:28592640_28592642delATC      c.2503_2505delGAT\                        rs121913486   COSM854              AML                                                0.99/--                                                    3
                  - In frame                                                                           cDNA.2585_2587delGAT\                                                                                                                                                                      
                                                                                                       g.82088_82090delGAT                                                                                                                                                                        

  D835A           Single base exchange - Substitution - Missense    chr13:28592641T\>G                 c.2504A\>C\                               --            COSM27650            AML\                                               0.99/0.99                                                  8
                                                                                                       cDNA.2586A\>C\                                                               ALL                                                                                                           
                                                                                                       g.82089A\>C                                                                                                                                                                                

  D835E           Single base exchange - Substitution - Missense    chr13:28592640A\>T                 c.2505T\>A\                               rs121913487   COSM787              AML                                                0.99/0.88                                                  8
                                                                                                       cDNA.2587T\>A\                                                                                                                                                                             
                                                                                                       g.82090T\>A                                                                                                                                                                                

  D835E           Single base exchange - Substitution - Missense    chr13:28592640A\>C                 c.2505T\>G\                               --            COSM788              AML                                                0.99/0.89                                                  6
                                                                                                       cDNA.2587T\>G\                                                                                                                                                                             
                                                                                                       g.82090T\>G                                                                                                                                                                                

  D835G           Deletion and insertion                            chr13:28592640_28592642delinsACC   c.2503_2505delinsGGT\                     --            --                   --                                                 0.99/0.99                                                  1
                                                                                                       cDNA.2585_2587delinsGGT\                                                                                                                                                                   
                                                                                                       g.82088_82090delinsGGT                                                                                                                                                                     

  D835H           Single base exchange - Substitution - Missense    chr13:28592642C\>G                 c.2503G\>C\                               rs121913488   COSM785              AML\                                               0.99/0.99                                                  9
                                                                                                       cDNA.2585G\>C\                                                               B ALL                                                                                                         
                                                                                                       g.82088G\>C                                                                                                                                                                                

  D835N           Single base exchange - Substitution - Missense    chr13:28592642C\>T                 c.2503G\>A\                               rs121913488   COSM789              AML\                                               0.99/0.99                                                  9
                                                                                                       cDNA.2585G\>A\                                                               ALL                                                                                                           
                                                                                                       g.82088G\>A                                                                                                                                                                                

  D835V           Single base exchange - Substitution - Missense    chr13:28592641T\>A                 c.2504A\>T\                               rs121909646   COSM784              AML\                                               0.99/0.99                                                  8
                                                                                                       cDNA.2586A\>T\                                                               ALL                                                                                                           
                                                                                                       g.82089A\>T                                                                                                                                                                                

  D835Y           Single base exchange - Substitution - Missense    chr13:28592642C\>A                 c.2503G\>T\                               rs121913488   COSM783              AML\                                               0.99/0.99                                                  9
                                                                                                       cDNA.2585G\>T\                                                               ALL                                                                                                           
                                                                                                       g.82088G\>T                                                                                                                                                                                

  I836-           Deletion - In frame                               chr13:28592635_28592637delATG      c.2508_2510delCAT cDNA.2590_2592delCAT\   rs121913490   COSM19836            AML\                                               0.99/--                                                    8
                                                                                                       g.82093_82095delCAT                                                          ALL\                                                                                                          
                                                                                                                                                                                    B ALL                                                                                                         

  -840S\          Insertion -- In frame                             chr13:28592624_28592625insGGATCC   c.2520_2521insGGATCC\                     rs398122514   COSM850              AML                                                0.99/--                                                    2
  -840G                                                                                                cDNA.2602_2603insGGATCC\                                                                                                                                                                   
                                                                                                       g.82105_82106insGGATCC                                                                                                                                                                     

  Y842C           Single base exchange -- Substitution - Missense   chr13:28592620T\>C                 c.2525A\>G\                               rs376588714   COSM19692            AML\                                               0.99/0.99                                                  2
                                                                                                       cDNA.2607A\>G\                                                               ALL                                                                                                           
                                                                                                       g.82110A\>G                                                                                                                                                                                
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AAE, amino acid exchange; DNA, Deoxyribonucleic acid; dbSNP, The Single Nucleotide Polymorphism Database; rs, reference SNP identifying number; COSMIC, The Catalogue of Somatic Mutations in Cancer; ID, identifier; FATHMM, Functional Analysis through Hidden Markov Models v2.3; AML, acute myeloid leukemia; ALL, acute lymphocytic leukemia; MDS, myelodysplastic syndrome; B ALL, B-cell acute lymphocytic leukemia; T ALL, T-cell acute lymphocytic leukemia

Quantification of the proportion of variant reads for a given mutation was made with variant allele frequency (VAF), which represents the percentage of tumor cells that harbor a specific mutation. The significantly highest mean VAF were observed for S451F (80.21%) and V592I (50.91%). The mean VAF for other mutations was below 20%.

The number of *FLT3* mutations in a single patient did not correlate with age (*r*-Pearson: --0.244, *p*-value: 0.25).

The frequency of occurrence of *FLT3* mutations in the tyrosine kinase domain was significantly higher in patients with a higher TNM stage, as all *FLT3*-positive patients with disease staging of pT2N1 and worse harbored at least one mutation in the tyrosine kinase domain ([Figure 1](#fig1-1758835920907534){ref-type="fig"}). Two *FLT3-*positive patients were considered refractory to radioactive iodine; in contrast, this was not observed in any *FLT3-*negative patient.

![*FLT3* mutational spectrum observed in follicular thyroid cancers -- distribution of acquired mutations in conjunction with the aggregation of the mutations into mutational categories: mutant (black), wild type (gray).](10.1177_1758835920907534-fig1){#fig1-1758835920907534}

Discussion {#section19-1758835920907534}
==========

This study demonstrates that the occurrence of *FLT3* mutations in patients with FTC is common, as 69% percent of those patients examined harbored at least one mutation in the *FLT3* gene. This variant has already been reported for the first time in *FTC* by our research team,^[@bibr26-1758835920907534]^ although had been previously known in AML, MDS, and hemangioblastoma.^[@bibr27-1758835920907534][@bibr28-1758835920907534][@bibr29-1758835920907534][@bibr30-1758835920907534]--[@bibr31-1758835920907534]^

Data concerning the presence of *FLT3* mutations in DTC cells are scarce. However, the application of novel techniques of genomic screening may enable detection of *FLT3* mutations in a histopathological specimen from patients with DTC. In a recent study by Gerber and colleagues targeted NGS was employed to detect genetic mutations in poorly differentiated thyroid cancer.^[@bibr32-1758835920907534]^ Analysis of 25 samples revealed the presence of the mutated *FLT3* gene in 16% of the analyzed specimens (in four patients). The reported mutations were of the missense type (G\>A substitution in positions 1734, 1969, 2455, 2503, and 2515 and C\>A substitution in position 2519 of cDNA). All detected mutations were previously reported in the COSMIC database as present in the hematopoietic and lymphoid tissue. Only substitutions in position 2503 of cDNA were common in our group of FTC patients and those reported by Gerber and colleagues.

In this study, a total of 26 mutations were found in the *FLT3* gene, of which some were previously described in the dbSNP or ExAC databases. All mutations had a somatic nature and were predicted to be disease-causing by Polyphen-2 and MutationTaster2, and oncogenic. The majority of *FLT3*-positive patients (58%) harbor mutations in the *FLT3* kinase domain ([Figure 1](#fig1-1758835920907534){ref-type="fig"}). The primary tumor may exhibit significant clonal heterogeneity, and this diversity may be affected during disease progression. Cellular dynamics of tumor evolution and heterotypic interactions between tumor subpopulations may still be possible. All these factors may, of course, make targeting FTC even more difficult, but maybe still possible, as the majority of the mutations is seen in the tyrosine kinase domain.

To discuss clonal composition and the character of the mutations we used a concept of analyzing VAF for the mutations. As has already been proven in hematological malignancies, the allelic burden of somatic mutations may be successfully incorporated even into clinical practice for the diagnosis and prognosis of neoplasms.^[@bibr33-1758835920907534]^ According to the VAF, we could hypothesize on the role of the mutations, especially in those cases with more than one alteration: the mutation with the greatest VAF would likely be the driver mutation.^[@bibr34-1758835920907534],[@bibr35-1758835920907534]^ We found that two mutations had a particular role in a possible natural history of FTC in our patients. S451F (localized in the extracellular domain) and V592I (in juxtamembrane domain) may be considered to be two oncogenic and driver mutations. Patients harbored one or both of these mutations. Analyzing their VAF, we may assume that their origin may be subclonal. A new finding of the possible particular role of those two mutations may be even more significant, taking into account their role as targets in the action of TKI, such as midostaurin. Further investigation with functional analysis is required to determine the functional role of all *FLT3* mutations detected in this cohort of patients.

Although an association between *FLT3* mutations and malignant disease, particularly in hematological malignancies, has been established, these findings are new for FTC. *FLT3* is known to be involved in the regulation of proliferation, differentiation, and survival of hematopoietic and dendritic cells.^[@bibr36-1758835920907534]^ Its occurrence is linked mainly with AML patients, as about 30% harbor the *FLT3* mutation, in which it is associated with reduced overall survival and increased risk of relapse compared with *FLT3*-negative AML patients.^[@bibr37-1758835920907534]^ *FLT3* was reported to be the single most commonly mutated gene in AML by Yamamato and colleagues in 2001.^[@bibr38-1758835920907534]^

Among the mutations within an activation loop, the most commonly found ones in our group of FTC patients concerned asparagine residues (Asp835) mutations, similarly to AML,^[@bibr39-1758835920907534]^ MDS, and ALL patients. As is the case of *FLT3*-internal tandem duplication (ITD), they spontaneously activate tyrosine kinase activity and induce factor-independent proliferation of hematopoietic cell lines.^[@bibr38-1758835920907534]^ Although the role of *FLT3* mutations in the transformation of myeloid cells is not yet known, it is highly probable that they provide a strong mitogenic and antiapoptotic signal.^[@bibr40-1758835920907534]^ Thus, these mutations may act synergistically with mutations blocking differentiation to induce AML and hypothetically, by analogy, FTC as well.

Not only kinase-activating mutations but also those located outside the juxtamembrane and kinase domains of *FLT3*, resulting in activated downstream signaling and conferred sensitivity to *FLT3* inhibition, may reduce kinase activity and promote cancer induction.^[@bibr39-1758835920907534],[@bibr41-1758835920907534]^ Among those were one of the most common point mutations in *FLT3*-positive patients, R834Q, which is expected to destabilize the autoinhibited kinase conformation and G831E that may stabilize *FLT3* in the autoinhibited conformation and result in reduced kinase activity. The effect on cell function has also been described for the S451F (localized in the extracellular domain), Y572C and V592G (in the juxtamembrane domain), and R834Q (in the activation loop) mutations of *FLT3*. These results suggest that there are not only differences in signal transduction between various *FLT3* mutation classes, that is, ITDs and activation loop mutations,^[@bibr42-1758835920907534],[@bibr43-1758835920907534]^ but also between distinct alleles within a given mutation class, which may affect specific signaling pathways differently.^[@bibr39-1758835920907534]^

This study indicates that neoplasms of different primary sites may also share a common genetic background, as has been found in other studies of various forms of cancer^[@bibr44-1758835920907534]^ and introduces the potential for a novel, genetic-based rather than histology-based cancer classification as a basis for targeted treatment.

The number of patients studied is insufficient to establish whether the inclusion of *FLT3* mutations may be used in the classification of FTC. However, the high rate of *FLT3* mutations found indicates that *FLT3* mutations are highly likely to play a role in the genesis of FTC. Further study, including an investigation into whether *FLT3* positivity is associated with RAI-refractory disease, is required in a larger cohort.

Although precautions were taken to minimize potential bias, limitations in the study include the sample size (35 FTC patients) although this is mitigated by the precise inclusion criteria, which increases the reliability of the results at the cost of reducing the study sample size. Genotyping of the selected mutations is required in more FTC patients before making firm conclusions. To simplify the interpretation of NGS results the description of the genetic findings were focused on *FLT3* mutations. However, Cancer Hotspot Panel v2, used for genetic analyses, included approximately 2800 COSMIC mutations from 50 oncogenes and tumor suppressor genes. Future work will include an analysis of other genetic mutations. Finally, the somatic type of the mutations has not been confirmed by NGS of peripheral DNA apart from the analysis in the first *FLT3* patient treated with a TKI. However, the familial occurrence of the disease was taken into account for all patients to exclude evidence of a mutation germline type.

For confirmation of the mutations, we used capillary Sanger sequencing in selected samples ([Figure 2](#fig2-1758835920907534){ref-type="fig"}). The method, however, has its limitations due to restricted sensitivity and its inability to perform parallel analysis of multiple targets, particularly in the case of cancer specimens. The limited sensitivity of Sanger sequencing of around 20% does not allow the investigation of sequence alterations detected by NGS at lower allele fractions. According to numerous recent reports, NGS platforms used in clinical and research settings are more accurate than Sanger sequencing.^[@bibr45-1758835920907534][@bibr46-1758835920907534]--[@bibr47-1758835920907534]^

![Sanger sequencing of commonly mutated codons of *FLT3* gene in patients with follicular thyroid cancer.](10.1177_1758835920907534-fig2){#fig2-1758835920907534}

An association between constitutive *FLT3* activation and disease prognosis makes this protein an attractive target for therapeutic intervention.^[@bibr48-1758835920907534]^ The most common types of *FLT3* mutations are ITD in the juxtamembrane domain and point mutations within the activation loop of *FLT3*,^[@bibr49-1758835920907534],[@bibr50-1758835920907534]^ leading to increased *FLT3* activation.^[@bibr40-1758835920907534]^ Furthermore, the study demonstrated that all *FLT3*-positive patients harbored at least one mutation in the *FLT3* tyrosine kinase domain. Currently, there are numerous selective *FLT3* inhibitors at various stages of clinical development, including sorafenib, lestaurtinib, tandutinib, quizartinib, sunitinib, midostaurin, gilteritinib, crenolanib, cabozantinib, Sel24-B489, G-749, AMG 925, TTT-3002, and FF-10101.^[@bibr51-1758835920907534],[@bibr52-1758835920907534]^ These compounds are well tolerated at doses that achieve *FLT3* inhibition and have shown moderate activity in AML patients with activating *FLT3* mutations, warranting an investigation into their potential applications to the treatment of radioiodine-refractory, *FLT3*-positive FTC patients. Midostaurin and gilteritinib have been approved by FDA for treatment of AML with *FLT3* mutations.^[@bibr52-1758835920907534]^

The potential association between *FLT3* mutations and the occurrence of RAI-refractory disease and metastases in older FTC patients may be useful for prognostic stratification and individualization of treatment.

This study demonstrates the potential of NGS to inform the development of individualization of therapy in patients with metastatic, iodine-refractory DTC. The index patient with metastatic, refractory FTC harbored *FLT3* D835H and *FLT3* D835Y mutations, which caused resistance to sorafenib^[@bibr22-1758835920907534],[@bibr24-1758835920907534]^ and may explain why the second line TKI treatment has not so far resulted in remission of the disease.

Conclusion {#section20-1758835920907534}
==========

There is a wide spectrum and high frequency of *FLT3* mutations in thyroid malignancy. The precise role of *FLT3* mutations in the genesis of FTC, as well as its potential role as a therapeutic target for individualized therapy with specific kinase inhibitors warrants further investigation.
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